1158 / 1578
/
Retrospective Analysis
Weickhardt JTO 2012
•
65 metastatic NSCLC patients
•
ALK+ and EGFR-MT treated with Crizotinib and Erlotinib, respectivey
Ø
Oligo-progression in 20 – 50%
Ø
Phase II EORTC HALT study in preparation
65 patients
Crizotinib
Erlotinib
25 / 51 of
progressive
patients:
SBRT
PFS
9-14 mo
6/25
Remained FFP
PFS
6 mo
Oligo-progression:
SBRT & systemic Tx beyond progression
07.09.17
ESTRO SBRT COURSE 2017 - Matthias Guckenberger
13
/ 07.09.17
ESTRO SBRT COURSE 2017 - Matthias Guckenberger
14
TKI
Oligo-
Progression
Widespread
Progression
SABR &
continue TKI
Continue TKI
Advanced NSCLC
EGFR / ALK + with response to TKI
Progression
Randomise (2:1)
HALT study in preparation
Ø
Oligo defined as max. 3 metastases
Ø
SBRT doses below 100Gy BED